Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Molidustat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN2 known ✓ | Q96KS0 | 12/20 | 1.00 |
| ▸ | EGLN1 known ✓ | Q9GZT9 | 2/20 | 1.00 |
| ▸ | EGLN3 known ✓ | Q9H6Z9 | 2/20 | 1.00 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 1.00 |
| ▸ | P4HTM | Q9NXG6 | 7/20 | 0.70 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Molidustat SCHEMBL29357358 | 1.00 | EGLN2 (1.00) | EGLN2EGLN1EGLN3HIF1ANP4HTM | |
| Molidustat SCHEMBL2570017 | 0.99 | EGLN2 (0.98) | EGLN2EGLN1EGLN3HIF1ANP4HTM | |
| SCHEMBL565272 | 0.96 | EGLN2 (0.92) | EGLN2EGLN1EGLN3HIF1ANP4HTM | |
| Hydrochloric Acid SCHEMBL564853 | 0.95 | EGLN2 (0.90) | EGLN2EGLN1EGLN3HIF1ANP4HTM | |
| SCHEMBL4752395 | 0.90 | EGLN2 (0.82) | EGLN2EGLN1EGLN3HIF1ANP4HTM | |
| SCHEMBL4752374 | 0.89 | EGLN2 (0.80) | EGLN2EGLN1EGLN3HIF1ANP4HTM | |
| SCHEMBL4259241 | 0.89 | EGLN2 (0.80) | EGLN2EGLN1EGLN3HIF1ANP4HTM | |
| SCHEMBL4752406 | 0.89 | EGLN2 (0.80) | EGLN2EGLN1EGLN3HIF1ANP4HTM | |
| Hydrochloric Acid SCHEMBL2571069 | 0.88 | EGLN2 (0.78) | EGLN2EGLN1EGLN3HIF1ANP4HTM | |
| SCHEMBL4752372 | 0.87 | EGLN2 (1.00) | EGLN2EGLN1EGLN3HIF1ANP4HTM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250319119-A1 | COMPOSITIONS AND METHODS THAT PROMOTE HYPOXIA OR THE HYPOXIA RESPONSE FOR TREATMENT AND PREVENTION OF MITOCHONDRIAL DYSFUNCTION AND OXIDATIVE STRESS DISORDERS | MASSACHUSETTS GEN HOSPITAL (US) | 2025-10-16 | — | — | US | claimed |
| EP-4512819-A2 | COMPOSITIONS AND METHODS THAT PROMOTE HYPOXIA OR THE HYPOXIA RESPONSE FOR TREATMENT AND PREVENTION OF MITOCHONDRIAL DYSFUNCTION AND OXIDATIVE STRESS DISORDERS | The General Hospital Corporation (US) | 2025-02-26 | — | — | EP | claimed |
| US-10301289-B2 | Method for the preparation of triazole compounds | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-05-28 | — | — | US | claimed |
| EP-3334484-A2 | COMPOSITIONS AND METHODS THAT PROMOTE HYPOXIA OR THE HYPOXIA RESPONSE FOR TREATMENT AND PREVENTION OF MITOCHONDRIAL DYSFUNCTION AND OXIDATIVE STRESS DISORDERS | The General Hospital Corporation (US) | 2018-06-20 | — | — | EP | claimed |
| EP-2847183-B1 | PROCESS FOR THE PREPARATION OF TRIAZOLE COMPOUNDS | Bayer Pharma AG (DE) | 2017-06-21 | — | — | EP | claimed |
| WO-2017027810-A2 | COMPOSITIONS AND METHODS THAT PROMOTE HYPOXIA OR THE HYPOXIA RESPONSE FOR TREATMENT AND PREVENTION OF MITOCHONDRIAL DYSFUNCTION AND OXIDATIVE STRESS DISORDERS | THE GENERAL HOSPITAL CORPORATION (US) | 2017-02-16 | — | — | WO | claimed |
| US-20160015786-A1 | MOBILIZING AGENTS AND USES THEREFOR | MATER MEDICAL RESEARCH INSTITUTE LIMITED (AU) | 2016-01-21 | — | — | US | claimed |
| US-20150087827-A1 | METHOD FOR THE PREPARATION OF TRIAZOLE COMPOUNDS | BAYER PHARMA AKTIENGESELLSCAFT (DE) | 2015-03-26 | — | — | US | claimed |
| US-8987261-B2 | Substituted dihydropyrazolones for treating cardiovascular and hematological diseases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-03-24 | — | — | US | claimed |
| US-20140031329-A1 | SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HEMATOLOGICAL DISEASES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-01-30 | — | — | US | claimed |
| EP-2084151-B1 | SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HAEMATOLOGICAL DISEASES | BAYER IP GMBH (DE) | 2013-05-29 | — | — | EP | claimed |
| US-8389520-B2 | Substituted dihydropyrazolones for treating cardiovascular and hematological diseases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-03-05 | — | — | US | claimed |
| US-12629357-B2 | Treatment of viral infections, of organ injury, and of related conditions using a HIF prolyl hydroxylase inhibitor or a HIF-alpha stabilizer | AKEBIA THERAPEUTICS, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| US-20250352527-A1 | METHODS FOR TREATING VIRAL INFECTIONS, ORGAN INJURY, AND RELATED CONDITIONS | AKEBIA THERAPEUTICS INC (US) | 2025-11-20 | — | — | US | disclosed |
| US-20250319119-A1 | COMPOSITIONS AND METHODS THAT PROMOTE HYPOXIA OR THE HYPOXIA RESPONSE FOR TREATMENT AND PREVENTION OF MITOCHONDRIAL DYSFUNCTION AND OXIDATIVE STRESS DISORDERS | MASSACHUSETTS GEN HOSPITAL (US) | 2025-10-16 | — | — | US | disclosed |
| US-12350290-B2 | Compositions and methods that promote hypoxia or the hypoxia response for treatment and prevention of mitochondrial dysfunction and oxidative stress disorders | THE GENERAL HOSPITAL CORPORATION (US) | 2025-07-08 | — | — | US | disclosed |
| US-20100305085-A1 | SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HEMATOLOGICAL DISEASES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-12-02 | — | — | US | disclosed |
| US-20100305085-A1 | SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HEMATOLOGICAL DISEASES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-12-02 | — | — | US | disclosed |
| US-20100305085-A1 | SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HEMATOLOGICAL DISEASES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-12-02 | — | — | US | disclosed |
| WO-2008067871-A1 | SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HAEMATOLOGICAL DISEASES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031329-A1 | SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HEMATOLOGICAL DISEASES | THPO, PFKP, DCK | EGLN2 250/4885EGLN1 828/4885EGLN3 220/4885 |
| US-20250352527-A1 | METHODS FOR TREATING VIRAL INFECTIONS, ORGAN INJURY, AND RELATED CONDITIONS | HIF1A, HIF1AN, EGLN3 | EGLN2 4/4885EGLN1 6/4885EGLN3 3/4885 |
| US-10301289-B2 | Method for the preparation of triazole compounds | CYP4B1, BRI3BP, BRD4 | EGLN2 1542/4885EGLN1 960/4885EGLN3 831/4885 |
| US-20150087827-A1 | METHOD FOR THE PREPARATION OF TRIAZOLE COMPOUNDS | CYP4B1, BRI3BP, BRD4 | EGLN2 1542/4885EGLN1 960/4885EGLN3 831/4885 |
| US-20100305085-A1 | SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HEMATOLOGICAL DISEASES | THPO, PFKP, HPGDS | EGLN2 44/4885EGLN1 219/4885EGLN3 46/4885 |
| US-12629357-B2 | Treatment of viral infections, of organ injury, and of related conditions using a HIF prolyl hydroxylase inhibitor or a HIF-alpha stabilizer | HIF1A, HIF1AN, EGLN3 | EGLN2 4/4885EGLN1 9/4885EGLN3 3/4885 |
| US-20160015786-A1 | MOBILIZING AGENTS AND USES THEREFOR | HIF1AN, CXCL12, HIF1A | EGLN2 6/4885EGLN1 10/4885EGLN3 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.